As previously reported, Northland analyst Carl Byrnes downgraded Esperion to Market Perform from Outperform with a price target of $60, down from $90, after the FDA label assigned to Nexletol fell short of his expectations by being limited to secondary prevention. While he thinks the safety language is not a cause for concern, Byrnes had expected the drug to be indicated for primary prevention and he significantly cut his U.S. peak sales forecast for the bempedoic acid franchise to about $1.25B from greater than $2B based on the label being restricted to secondary prevention.